Anteris Technologies Global Corp. (ASX:AVR)
9.59
+0.04 (0.42%)
Oct 12, 2026, 4:10 PM AEST
ASX:AVR Revenue
Anteris Technologies Global had revenue of $1.01M USD in the quarter ending June 30, 2026, with 63.27% growth. This brings the company's revenue in the last twelve months to $2.24M, down -9.56% year-over-year. In the year 2025, Anteris Technologies Global had annual revenue of $1.91M, down -29.23%.
Revenue (ttm)
$2.24M
Revenue Growth
-9.56%
P/S Ratio
291.85
Revenue / Employee
$12.89K
Employees
174
Market Cap
945.82M AUD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.91M | -790.00K | -29.23% |
| Dec 31, 2024 | 2.70M | -32.00K | -1.17% |
| Dec 31, 2023 | 2.74M | -384.72K | -12.33% |
| Dec 31, 2022 | 3.12M | -2.55M | -44.93% |
| Dec 31, 2021 | 5.66M | 203.73K | 3.73% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cochlear | 2.35B |
| PolyNovo | 149.85M |
| Saluda Medical | 130.35M |
| SomnoMed | 114.53M |
| Aroa Biosurgery | 86.47M |
| Lumos Diagnostics Holdings | 19.07M |
| EBR Systems | 9.32M |
| EMVision Medical Devices | 8.36M |
Anteris Technologies Global News
- 6 weeks ago - Anteris to Present at September Healthcare Investor Conferences - GlobeNewsWire
- 2 months ago - Anteris Technologies Announces Results for the Second Quarter of 2026 - GlobeNewsWire
- 4 months ago - Anteris Advances Global PARADIGM Expansion with French Regulatory Clearance - GlobeNewsWire
- 5 months ago - Anteris Appoints Susan Knight and Stephen Denaro to its Board of Directors - GlobeNewsWire
- 5 months ago - Anteris Announces Results for the First Quarter of 2026 - GlobeNewsWire
- 5 months ago - Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial - GlobeNewsWire
- 5 months ago - Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial - GlobeNewsWire
- 7 months ago - Anteris Reports 2025 Financial Results and Provides Corporate Update - GlobeNewsWire